ACRX AcelRx Pharmaceuticals Inc.

3.20
+0.00  (0%)
Previous Close 3.20
Open 3.25
Price To book -4.57
Market Cap 145217514
Shares 45,380,473
Volume 900,867
Short Ratio 4.05
Av. Daily Volume 1,447,328

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171047405
  2. 8-K - Current report 171046147
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17997905
  4. 8-K - Current report 17994683
  5. 8-K - Current report 17970602

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
PDUFA date October 12, 2017. Noted June 7, 2017 that an Advisory Committee Meeting is no longer planned.
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. Additional clinical trial required. Phase 3 trial initiated September 2016. Data released August 1, 2017 with NDA to be refiled by the end of 2017.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. AcelRx Upcoming FDA Review, Analyst Target Price and Pipeline Review
  2. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : September 11, 2017
  3. AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
  4. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : August 31, 2017
  5. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
  6. Edited Transcript of ACRX earnings conference call or presentation 1-Aug-17 12:30pm GMT
  7. AcelRx Pharmaceuticals Inc (ACRX) Could Face Opioid Heat from FDA with Zalviso, Worries Roth Capital
  8. Investor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call
  9. Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Incyte Corporation
  10. AcelRx Pharmaceuticals reports 2Q loss
  11. AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  12. AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality
  13. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 31, 2017
  14. AcelRx Pharmaceuticals to Hold a Conference Call and Webcast on Tuesday, August 1st to Discuss ZALVISO Phase 3 Top-line Data and Quarterly Financial Results
  15. AcelRx Pharmaceuticals to Hold Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2nd
  16. AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
  17. Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics
  18. Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target
  19. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 30, 2017

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171047405
  2. 8-K - Current report 171046147
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17997905
  4. 8-K - Current report 17994683
  5. 8-K - Current report 17970602
  6. 8-K - Current report 17920996
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17914049
  8. EFFECT - Notice of Effectiveness 17912319
  9. 8-K - Current report 17895553
  10. S-3 - Registration statement under Securities Act of 1933 17891931